Back to top
more

AxoGen, Inc. (AXGN)

(Delayed Data from NSDQ)

$15.31 USD

15.31
407,722

-0.28 (-1.80%)

Updated Nov 20, 2019 04:00 PM ET

Pre-Market: $15.30 -0.01 (-0.07%) 7:57 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | D Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGN

Zacks Equity Research

Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

Zacks Equity Research

AxoGen (AXGN) Reports Q2 Loss, Misses Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGN

Zacks Equity Research

Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

Zacks Equity Research

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGN

Zacks Equity Research

Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

Zacks Equity Research

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

MASI DXCM WMGI AXGN

Zacks Equity Research

What's in Store for Humana (HUM) Stock in Q4 Earnings?

Higher enrollment and strong segmental results are expected to help Humana (HUM) in fourth-quarter earnings.

AXGN MOH HUM THC

Zacks Equity Research

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AXGN

Zacks Equity Research

AxoGen (AXGN) Q3 Earnings Preview: What's in the Cards?

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

Kevin Cook

Bull of the Day: Penumbra (PEN)

Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech

SYK PEN MZOR MDT JNJ IART EW BAX AXGN ABT

Zacks Equity Research

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

DWAS PLUS MRTX AXGN

Zacks Equity Research

Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1

Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.

AGN RDY TEVA AXGN

Sweta Killa

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

DWAS MGPI MRTX AXGN

Sweta Killa

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

DWAS NEOG MRTX AXGN

Zacks Equity Research

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

DWAS MGPI NEOG AXGN

Zacks Equity Research

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

DWAS AXGN ASGN MDGL

Zacks Equity Research

AxoGen (AXGN) Enters Overbought Territory

AxoGen, Inc. (AXGN) has moved higher as of late, but there could definitely be trouble on the horizon for this company

AXGN

Zacks Equity Research

Mylan (MYL) Surges: Stock Moves 16.2% Higher

Mylan N.V. (MYL) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes.

MYL AXGN

Zacks Equity Research

AxoGen (AXGN) Shows Strength: Stock Adds 6.1% in Session

AxoGen, Inc. (AXGN) shares rose a little above 6% in the last trading session.

AXGN CORI

Zacks Equity Research

Zacks.com featured highlights: AxoGen, MAG Silver, Triumph Bancorp, UCP and Yelp

Zacks.com featured highlights: AxoGen, MAG Silver, Triumph Bancorp, UCP and Yelp

AXGN MAG TBK